Early Tuesday morning, Rigel Pharmaceuticals (NASDAQ: RIGL) and its now-ex-partner, AstraZeneca (NYSE: AZN), reported late-stage clinical trial results for the experimental rheumatoid arthritis drug Fostamatinib. In the following video, health-care analyst Max Macaluso discusses why Rigel dropped 18% after the news was released and the risks that lie ahead for Rigel Pharmaceuticals.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.